“Every oncologist, every researcher, every IRB has got to know about that study.” @DrMaurieMarkman, on why LACC tops his ranking of landmark gynecologic oncology trials on Double Blind. Watch: piped.video/watch?v=4KcWCXiR…

🚨 The Weekly Roundup is here! 📖 Tune in for a detailed breakdown of the top abstracts at this year's ESMO Congress! From INTerpath-001 to AZUR-1, from DeLLphi-305 to KEYNOTE-C93, from NATALEE to PROTEUS! Subscribe on LinkedIn hubs.li/Q04CXbFN0 #ESMO26 #pancsm #lcsm #bcsm #crcsm #melsm #ONCOLOGY

💡 The ONCOLOGY Monthly Spotlight with Yan Leyfman, MD (@YLeyfman), is here! 📝 The Usefulness of Indocyanine Green in Cytoreductive Ovarian Cancer Surgery 🔗 cancernetwork.com/view/the-u… #gyncsm #ovariancancer #ONCOLOGY #cancer #surgery

Check out the GI data that stood out at #ESMO26, from phase 1 to phase 3: 📊 INCB161734 + mFOLFIRINOX 📊 Dostarlimab in dMMR rectal cancer 📊 Ivonescimab plus gemcitabine/cisplatin in biliary tract cancer 🔗 hubs.li/Q04CTydR0 #GIcancer #gicsm #oncology #cancer

ASTRO now recommends moderate hypofractionation for all risk groups and SBRT as a standard option in low- and intermediate-risk localized prostate cancer. hubs.li/Q04CQX-X0 #pcsm #ProstateCancer #oncology #cancer

💡 The ONCOLOGY Monthly Spotlight will be here tomorrow! Tune in to Yan Leyfman, MD (@YLeyfman), to learn more about indocyanine green's usefulness for ovarian cancer surgery? ⬇️ Check out the study here ⬇️ hubs.li/Q04CQPwJ0 #gyncsm #surgery #oncology #cancer

A systematic literature review supplemented by AI tools identified 36 fit-for-use real-world data (RWD) sources evaluating homologous recombination repair (HRR) gene mutations in prostate cancer, according to a poster presentation at #ESMO26. The study highlighted critical gaps: sources with detailed HRR biomarker testing often lacked comorbidity and non-cancer treatment details, while comprehensive clinical datasets frequently lacked biomarker data. #pcsm #PrecisionOncology #RealWorldData #AIinOncology

Prospective data presented at #ESMO26 demonstrate the feasibility and accuracy of AI-assisted RECIST 1.1 response evaluation in a phase 1 study (NCT05208762) of fetrastobart vedotin (Fetra-V) in NSCLC. AI-assisted reads showed high concordance with investigator-assessed confirmed ORR and DCR while significantly improving inter-reader reproducibility and reducing read time by 40% at baseline and 52% at follow-up (P <.001). #NSCLC #DigitalHealth #AIinOncology

First-line sac-TMT + pembro prolonged PFS vs chemo + pembro in PD-L1– advanced nonsquamous NSCLC without targetable genomic alterations. hubs.li/Q04CH3MC0 #lcsm #NSCLC #oncology #cancer

💡 How was useful was indocyanine green (ICG) for detecting ovarian cancer lesions for surgery? Listen to Yan Leyfman, MD (@YLeyfman), in this edition of the ONCOLOGY Monthly Spotlight. Coming soon! ⬇️ Check out the study here ⬇️ hubs.li/Q04CGTQk0 #gyncsm #ovariancancer #oncology #cancer

🤔 Want to stay up to date on top #ESMO2026 in melanoma and skin cancer? Catch up on all the data now 👇 cancernetwork.com/view/melan…

Etentamig, a second-generation BCMA/CD3 bispecific antibody T-cell engager, was supported by results from the CERVINO trial. The agent significantly improved ORR and PFS vs investigator’s choice of standard available therapies in relapsed or refractory multiple myeloma. hubs.li/Q04CwWnr0 #mmsm #myeloma #oncology #cancer

Initial data from the ROSETTA Lung-107 trial support further study of pumitamig in metastatic NSCLC previously managed with an immunotherapy-based regimen. hubs.li/Q04CwSTL0 #lcsm #NSCLC #oncology #cancer

💡 So little time has passed but our next Monthly ONCOLOGY Spotlight, with Yan Leyfman, MD (@YLeyfman), is already on the way! 📝 The Usefulness of Indocyanine Green in Cytoreductive Ovarian Cancer Surgery ⬇️ Check out the study here ⬇️ hubs.li/Q04CtKqc0 #gyncsm #ovariancancer #oncology #cancer

First-line ivonescimab plus gemcitabine/cisplatin significantly prolonged overall survival vs durvalumab plus chemo in patients with advanced biliary tract cancer. hubs.li/Q04Cnzbk0 #gicsm #hpbcsm #oncology #cancer

🎙️ What should radiation oncologists know from #ASTRO2026? @brandonmancini breaks down key data from PACE-A, MAVERICK, and Alliance A071801 in the latest RadOnc on the Run episode. Watch now: hubs.li/Q04Cct9Y0 #RadOnc #Oncology

Sac-TMT significantly improved survival and responses vs TPC in advanced or recurrent endometrial cancer that had received platinum-based chemotherapy and immunotherapy. hubs.li/Q04Cnxrt0 #gyncsm #EndometrialCancer #oncology

The FDA has approved talazoparib plus enzalutamide in metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations. hubs.li/Q04CkbG30 #pcsm #prostatecancer #oncology #cancer | @FDA

How can proactive supportive care help patients stay on treatment with subcutaneous amivantamab plus lazertinib? Wade T. Iams, MD of @TNOncology and @LuisRaezMD discuss COPERNICUS study design, prophylaxis, and brain metastases. ▶️ Watch now: hubs.li/Q04yXthz0 #NSCLC #EGFR

Combining frontline ivonescimab with gemcitabine/cisplatin chemotherapy signficantly prolonged OS vs durvalumab plus chemotherapy among those with advanced biliary tract cancer. The phase 3 HARMONi-GI1 trial demonstrated that first-line ivonescimab plus chemotherapy may be a new standard of care in this patient population. hubs.li/Q04Cfh410 #gicsm #ESMO26 | @myESMO

Osimertinib plus savolitinib significantly improved PFS and OS vs platinum/pemetrexed chemotherapy in patients with EGFR-mutated, locally advanced or metastatic NSCLC with MET overexpression, MET amplification, or both whose disease had progressed during osimertinib therapy. Data from the phase 3 SAFFRON trial may support osimertinib plus savolitinib as a new global standard of care in this EGFR-mutated NSCLC population. hubs.li/Q04Cfh1W0 #lcsm #ESMO26 | @myESMO